Shares of Can-Fite BioPharma Ltd. (CANF) climbed more than 36% on Wednesday morning after the company announced positive Phase 2a results for its pancreatic cancer candidate, Namodenoson.
The stock is currently trading at $4.06, up $1.09 or 36.73%, on the NYSE American. It opened at $5.02 after closing the previous session at $2.97. The stock has traded between $2.56 and $21.00 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.